441 related articles for article (PubMed ID: 16351642)
21. Thrombin generation and fibrin clot structure.
Wolberg AS
Blood Rev; 2007 May; 21(3):131-42. PubMed ID: 17208341
[TBL] [Abstract][Full Text] [Related]
22. Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B.
Goldenberg NA; Bombardier C; Hathaway WE; McFarland K; Jacobson L; Manco-Johnson MJ
Haemophilia; 2008 Jan; 14(1):68-77. PubMed ID: 18005147
[TBL] [Abstract][Full Text] [Related]
23. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
24. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.
Jilma B; Marsik C; Mayr F; Graninger MT; Taylor FB; Ribel MC; Erhardtsen E; Handler S; Eichler HG
Clin Pharmacol Ther; 2002 Oct; 72(4):403-10. PubMed ID: 12386642
[TBL] [Abstract][Full Text] [Related]
26. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
27. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
[TBL] [Abstract][Full Text] [Related]
28. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
Hoffman M; Monroe DM; Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S61-5. PubMed ID: 9819030
[TBL] [Abstract][Full Text] [Related]
29. Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation.
Mitrophanov AY; Reifman J
Thromb Res; 2011 Oct; 128(4):381-90. PubMed ID: 21641634
[TBL] [Abstract][Full Text] [Related]
30. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
31. First 20 years with recombinant FVIIa (NovoSeven).
Hedner U; Lee CA
Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
[TBL] [Abstract][Full Text] [Related]
32. Basic aspects of bypassing agents.
Negrier C; Dargaud Y; Bordet JC
Haemophilia; 2006 Dec; 12 Suppl 6():48-52; discussion 52-3. PubMed ID: 17123394
[TBL] [Abstract][Full Text] [Related]
33. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
34. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
35. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
36. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
Li R; Panckeri KA; Fogarty PF; Diamond SL
Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
[TBL] [Abstract][Full Text] [Related]
37. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
[TBL] [Abstract][Full Text] [Related]
38. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Hedner U
Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
[TBL] [Abstract][Full Text] [Related]
39. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
40. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
